HaiXin Rhett Biomedical Technology Co., Shanghai, starts pilot-scale production of recombinant human serum albumen in Shanghai

Oct 15, 2012

The company has developed technology for production and purification to injection-grade hSA in the lab scale. A pilot plant for production will now be established at Shanghai’s Zhangjiang Center for Biomedicine Development.

Science Daily, Oct. 15, 2012

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny